Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma

Overview of attention for article published in Frontiers in oncology, September 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 24,720 followers.

New article: Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma https://t.co/lRcvs5Sx40 #melanoma #oncology https://t.co/fHqGgJivyj

10 Oct 2022

Reply Repost Favourite

Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma: Combination dabrafenib (D) and trametinib (T) is an FDA approved adjuvant therapy for patients with resected stage III… #oncology https://t.co/hIn

24 Sep 2022

Reply Repost Favourite

New research: Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma: Combination dabrafenib (D) and trametinib (T) is an FDA approved adjuvant therapy for patients with resected stage III… https://t.co/

24 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.